By

Stephanie Ciardi
Hunting Dog Capital: Intelligent Growth Capital for the Lower Middle-Market Hunting Dog Capital is a San Francisco-based investment manager founded in 2006 that specializes in providing flexible financing, primarily in the form of senior-secured term loans, to lower middle-market U.S. later-stage companies. Business owners use the loans to facilitate acquisitions, refinance existing debt or for...
Read More
Elevian – Reimagine Aging Elevian is a Harvard spin-out developing new medicines that target aging.  These drugs have the potential to treat and prevent many age-related diseases at the same time and extend healthy longevity. Groundbreaking research by Elevian’s scientific founders has demonstrated that older animals, when transfused with the blood of young animals, experience...
Read More
Sunman Exhibits at Art Basel Artwork by Family Office Networks’ Art Director “Sunman” was exhibited on Wednesday, December 4th at Miami Art Mob’s Grand Opening at the Historic Downtown Miami Macy’s Building – 2nd Floor Gallery. Art, Drinks and Music were featured and Miami Marine Stadium’s “If Seats Could Talk” gorgeous and historic seat artworks were exhibited...
Read More
Family Office Networks Announces Publication of Luxury Lifestyle Magazine Holiday Issue Palm Beach, FL – (November 26, 2019) – The holiday issue of Family Office Networks’ new luxury lifestyle magazine debuted this week representing the second issue and featuring a series of articles on topics such as Raising High Net Worth Children in the Age of...
Read More
Anthemis releases Embedded Finance, a white paper on the future of the economy Anthemis sees the future state of financial services as embedded, augmented and ubiquitous. Rather than finance being discrete, Anthemis believes it is becoming an intimate part of the products and services that drive our economies — an often invisible but critical societal...
Read More
How to Invest in Biotech Series – Phases, Stages, and Pitfalls By Marc Appel, CEO, Orange Grove Bio Emily Whitehead was 5 years old when she was diagnosed with acute lymphoblastic leukemia, a serious yet the most common type of childhood cancer. Her cancer was resistant to traditional treatments and her prognosis was poor. In...
Read More
BioXyTran, Inc. — Tissue Regeneration for Life Bioxytran Inc. (OTC: BIXT) is a late stage biotechnology company that is developing a first-in-class oxygen treatment platform for victims of brain stroke trauma. The company’s lead drug candidate, BXT-25, is getting ready to proceed to testing.  BXT-25 has many properties of an existing, well tested drug, called...
Read More
Orange Grove Bio: Filling the Gap in Preclinical Drug Development Future Orange Grove Bio is a preclinical drug development company focused on driving down the cost of drug development and taking advantage of the exceptional science developed at universities across the country. Preclinical biopharma today represents one of the best opportunities in life sciences today....
Read More
Selecting Therapies for Cancer Patients: Past, Present, and Future Clifford Reid, PhD We are in the middle of a revolution in DNA sequencing, which has ushered in the era of precision medicine in cancer. Unfortunately, the impact of precision medicine has been quite limited, reaching only about 15% of cancer patients, and benefitting only about...
Read More
An Interview with Kristin Bedard PhD, Chief Scientific Officer Kineta Immuno-Oncology. KINETA, INC. – Innovation in Cancer Care, New Drugs in High Need Areas (PART 2). Part 2 In two previous articles, our readers were introduced to the Kineta, Inc. CEO Shawn Iadonato and Kristin Bedard PhD, the Chief Scientific Officer at the company.  In...
Read More
1 2 3

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Our Cases